Difference between revisions of "Talk:Programmed death-ligand 1"

From Libre Pathology
Jump to navigation Jump to search
Line 12: Line 12:


CPS in lymph nodes:
CPS in lymph nodes:
https://pubmed.ncbi.nlm.nih.gov/35420378/
*H&N: https://pubmed.ncbi.nlm.nih.gov/35420378/ https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/
https://pmc.ncbi.nlm.nih.gov/articles/PMC7413953/
*Breast: https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/ https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z
https://pmc.ncbi.nlm.nih.gov/articles/PMC10078903/
https://surgexppathol.biomedcentral.com/articles/10.1186/s42047-019-0033-z


==References==
==References==
{{Reflist|1}}
{{Reflist|1}}

Revision as of 15:22, 29 October 2024

Urothelial carcinoma

Urothelial carcinoma - atezolizumab[1]

Renal cell carcinoma

  • 2015 paper: ~ 15% respond to PD-L1[1]
    • Biomarkers predict response
  • 2018 paper: ~ 70% durable response among those that discontinue d/t side effects[2]
  • 2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[3]
  • 2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[4]

CPS and TPS

CPS in lymph nodes:

References

  1. Rosenberg, JE.; Hoffman-Censits, J.; Powles, T.; van der Heijden, MS.; Balar, AV.; Necchi, A.; Dawson, N.; O'Donnell, PH. et al. (May 2016). "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.". Lancet 387 (10031): 1909-20. doi:10.1016/S0140-6736(16)00561-4. PMID 26952546.